State Street
KAPA

State Street’s Kairos Pharma KAPA Stock Holding History

State Street’s Portfolio KAPA Stock Details KAPA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$13.5K Hold
24,100
– – ﹤0.01% 4239
2025
Q4 		$17.1K Hold
24,100
– – ﹤0.01% 4251
2025
Q3 		$28.2K Buy
+24,100
New +$27.5K ﹤0.01% 4220

Other funds holding KAPA

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
SFG
SevenBridge Financial Group Harrisburg, Pennsylvania $640M AUM 27.29% 1-Year Est. Return
ACA
Aptus Capital Advisors Fairhope, Alabama $12.7B AUM 17.41% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return

State Street's KAPA Position: Q1 2026 in Review

State Street held its Kairos Pharma (KAPA) position steady in Q1 2026 at 24,100 shares worth $13.5K. The position accounts for ﹤0.01% of the portfolio, ranked #4239.

State Street first reported a position in KAPA in Q3 2025 and has held it in 3 quarters since. The position peaked at $28.2K in Q3 2025. 11 funds tracked by Wall St. Rank hold KAPA as of Q1 2026.

  • State Street held 24,100 shares of Kairos Pharma worth $13.5K as of Q1 2026.
  • State Street left its Kairos Pharma share count unchanged in Q1 2026.
  • Kairos Pharma made up ﹤0.01% of State Street's portfolio in Q1 2026, its #4239 holding.
  • State Street first reported a position in Kairos Pharma in Q3 2025 and has held it in 3 quarters since.
  • State Street's Kairos Pharma position peaked at $28.2K in Q3 2025.
  • 11 funds tracked by Wall St. Rank held Kairos Pharma as of Q1 2026.

Based on State Street's 13F filing for Q1 2026, filed 15 May 2026.